Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 506

1.

Viral protein X Reduces the Incorporation of Mutagenic Noncanonical rNTPs during Lentivirus Reverse Transcription in Macrophages.

Oo A, Kim DH, Schinazi RF, Kim B.

J Biol Chem. 2019 Dec 5. pii: jbc.RA119.011466. doi: 10.1074/jbc.RA119.011466. [Epub ahead of print]

2.

Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.

Abreu RM, Bassit LC, Tao S, Jiang Y, Ferreira AS, Hori PC, Ganova-Raeva LM, Khudyakov Y, Schinazi RF, Carrilho FJ, Ono SK.

Antivir Ther. 2019 Dec 4. doi: 10.3851/IMP3338. [Epub ahead of print]

PMID:
31799942
3.

Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus.

Liu D, Tedbury PR, Lan S, Huber AD, Puray-Chavez MN, Ji J, Michailidis E, Saeed M, Ndongwe TP, Bassit LC, Schinazi RF, Ralston R, Rice CM, Sarafianos SG.

Viruses. 2019 Nov 8;11(11). pii: E1039. doi: 10.3390/v11111039.

4.

Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses in Vitro and in Humanized Mice.

Amblard F, Boucle S, Bassit L, Cox B, Sari O, Tao S, Chen Z, Ozturk T, Verma K, Russell O, Rat V, de Rocquigny H, Fiquet O, Boussand M, Di Santo J, Strick-Marchand H, Schinazi RF.

Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01701-19. doi: 10.1128/AAC.01701-19. [Epub ahead of print]

PMID:
31712213
5.

Disentangling the lifespans of hepatitis C virus-infected cells and intracellular vRNA replication-complexes during direct-acting anti-viral therapy.

Cardozo EF, Ji D, Lau G, Schinazi RF, Chen GF, Ribeiro RM, Perelson AS.

J Viral Hepat. 2019 Oct 31. doi: 10.1111/jvh.13229. [Epub ahead of print]

PMID:
31670859
6.

Effect of induced dNTP pool imbalance on HIV-1 reverse transcription in macrophages.

Shepard C, Xu J, Holler J, Kim DH, Mansky LM, Schinazi RF, Kim B.

Retrovirology. 2019 Oct 26;16(1):29. doi: 10.1186/s12977-019-0491-0.

7.

Intracellular metabolism and potential cardiotoxicity of a β-D-2'-C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication.

Tao S, Zhou L, Zhang H, Zhou S, Amiralaei S, Shelton J, Ehteshami M, Jiang Y, Amblard F, Coats SJ, Schinazi RF.

Nucleosides Nucleotides Nucleic Acids. 2019 Oct 9:1-21. doi: 10.1080/15257770.2019.1671594. [Epub ahead of print]

PMID:
31595843
8.

Synthesis of 7-trifluoromethyl-7-deazapurine ribonucleoside analogs and their monophosphate prodrugs.

Cho JH, Bassit LC, Amblard F, Schinazi RF.

Nucleosides Nucleotides Nucleic Acids. 2019 Oct 7:1-17. doi: 10.1080/15257770.2019.1674333. [Epub ahead of print]

PMID:
31588837
9.

Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro.

Gavegnano C, Haile WB, Hurwitz S, Tao S, Jiang Y, Schinazi RF, Tyor WR.

J Neuroinflammation. 2019 Sep 27;16(1):182. doi: 10.1186/s12974-019-1565-6.

10.

Efficient pre-catalytic conformational change of reverse transcriptases from SAMHD1 non-counteracting primate lentiviruses during dNTP incorporation.

Coggins SA, Holler JM, Kimata JT, Kim DH, Schinazi RF, Kim B.

Virology. 2019 Nov;537:36-44. doi: 10.1016/j.virol.2019.08.010. Epub 2019 Aug 14.

11.
12.

Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus.

Zandi K, Amblard F, Amichai S, Bassit L, Tao S, Jiang Y, Zhou L, Ollinger Russell O, Mengshetti S, Schinazi RF.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00889-19. doi: 10.1128/AAC.00889-19. Print 2019 Sep.

PMID:
31262759
13.

Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses.

Zandi K, Bassit L, Amblard F, Cox BD, Hassandarvish P, Moghaddam E, Yueh A, Libanio Rodrigues GO, Passos I, Costa VV, AbuBakar S, Zhou L, Kohler J, Teixeira MM, Schinazi RF.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00397-19. doi: 10.1128/AAC.00397-19. Print 2019 Jul.

PMID:
31061163
14.

Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals.

Mukonzo J, Aklillu E, Marconi V, Schinazi RF.

Int J Infect Dis. 2019 Jun;83:98-101. doi: 10.1016/j.ijid.2019.04.009. Epub 2019 Apr 13.

15.

A global scientific strategy to cure hepatitis B.

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e7.

16.

Correction for Mavigner et al., "Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques".

Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, Kashuba A, Amblard F, Schinazi RF, Lawson B, Vanderford TH, Jean S, Cohen J, McGary C, Paiardini M, Wood MP, Sodora DL, Silvestri G, Estes J, Chahroudi A.

J Virol. 2019 Jan 17;93(3). pii: e01814-18. doi: 10.1128/JVI.01814-18. Print 2019 Feb 1. No abstract available.

17.

Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs.

Ovadia R, Khalil A, Li H, De Schutter C, Mengshetti S, Zhou S, Bassit L, Coats SJ, Amblard F, Schinazi RF.

Bioorg Med Chem. 2019 Feb 15;27(4):664-676. doi: 10.1016/j.bmc.2019.01.005. Epub 2019 Jan 9.

PMID:
30655167
18.

Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.

Mengshetti S, Zhou L, Sari O, De Schutter C, Zhang H, Cho JH, Tao S, Bassit LC, Verma K, Domaoal RA, Ehteshami M, Jiang Y, Ovadia R, Kasthuri M, Ollinger Russell O, McBrayer T, Whitaker T, Pattassery J, Pascual ML, Uher L, Lin BY, Lee S, Amblard F, Coats SJ, Schinazi RF.

J Med Chem. 2019 Feb 28;62(4):1859-1874. doi: 10.1021/acs.jmedchem.8b01300. Epub 2019 Feb 7.

PMID:
30653317
19.

Structural and Antiviral Studies of the Human Norovirus GII.4 Protease.

Muzzarelli KM, Kuiper B, Spellmon N, Brunzelle J, Hackett J, Amblard F, Zhou S, Liu P, Kovari IA, Yang Z, Schinazi RF, Kovari LC.

Biochemistry. 2019 Feb 19;58(7):900-907. doi: 10.1021/acs.biochem.8b01063. Epub 2019 Jan 16.

PMID:
30605321
20.

Disparate effects of cytotoxic chemotherapy on the antiviral activity of antiretroviral therapy: implications for treatments of HIV-infected cancer patients.

Medina-Moreno S, Zapata JC, Cottrell ML, Le NM, Tao S, Bryant J, Sausville E, Schinazi RF, Kashuba AD, Redfield RR, Heredia A.

Antivir Ther. 2019;24(3):177-186. doi: 10.3851/IMP3285.

21.

Host SAMHD1 protein restricts endogenous reverse transcription of HIV-1 in nondividing macrophages.

Mahboubi B, Gavegnano C, Kim DH, Schinazi RF, Kim B.

Retrovirology. 2018 Oct 13;15(1):69. doi: 10.1186/s12977-018-0452-z.

22.

Interplay of ancestral non-primate lentiviruses with the virus-restricting SAMHD1 proteins of their hosts.

Mereby SA, Maehigashi T, Holler JM, Kim DH, Schinazi RF, Kim B.

J Biol Chem. 2018 Oct 19;293(42):16402-16412. doi: 10.1074/jbc.RA118.004567. Epub 2018 Sep 4.

23.

Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.

Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, Gavegnano C, Schinazi RF, Poznansky MC.

Oncotarget. 2018 Jul 13;9(54):30472. doi: 10.18632/oncotarget.25791. eCollection 2018 Jul 13.

24.

Template-assisted synthesis of adenine-mutagenized cDNA by a retroelement protein complex.

Handa S, Jiang Y, Tao S, Foreman R, Schinazi RF, Miller JF, Ghosh P.

Nucleic Acids Res. 2018 Oct 12;46(18):9711-9725. doi: 10.1093/nar/gky620.

25.

Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques.

Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, Kashuba A, Amblard F, Schinazi RF, Lawson B, Vanderford TH, Jean S, Cohen J, McGary C, Paiardini M, Wood MP, Sodora DL, Silvestri G, Estes J, Chahroudi A.

J Virol. 2018 Aug 29;92(18). pii: e00562-18. doi: 10.1128/JVI.00562-18. Print 2018 Sep 15. Erratum in: J Virol. 2019 Jan 17;93(3):.

26.

Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors.

Amblard F, Zhou S, Liu P, Yoon J, Cox B, Muzzarelli K, Kuiper BD, Kovari LC, Schinazi RF.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2165-2170. doi: 10.1016/j.bmcl.2018.05.012. Epub 2018 May 8.

27.

Expression, Purification and Characterization of a GII.4 Norovirus Protease from Minerva Virus.

Kuiper BD, Muzzarelli KM, Keusch BJ, Holcomb J, Amblard F, Liu P, Zhou S, Kovari IA, Yang Z, Schinazi RF, Kovari LC.

Infect Disord Drug Targets. 2018;18(3):224-232. doi: 10.2174/1871526518666180521091158.

PMID:
29779487
28.

Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?

Asselah T, Marcellin P, Schinazi RF.

Liver Int. 2018 Feb;38 Suppl 1:7-13. doi: 10.1111/liv.13673. Review.

PMID:
29427484
29.

Towards HBV curative therapies.

Schinazi RF, Ehteshami M, Bassit L, Asselah T.

Liver Int. 2018 Feb;38 Suppl 1:102-114. doi: 10.1111/liv.13656. Review.

30.

Mobile Health Intervention to Reduce HIV Transmission: A Randomized Trial of Behaviorally Enhanced HIV Treatment as Prevention (B-TasP).

Kalichman SC, Cherry C, Kalichman MO, Eaton LA, Kohler JJ, Montero C, Schinazi RF.

J Acquir Immune Defic Syndr. 2018 May 1;78(1):34-42. doi: 10.1097/QAI.0000000000001637.

31.

Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.

Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, Cameron C, Santos S, Hurwitz SJ, Marconi VC, Routy JP, Sabbagh L, Schinazi RF, Sékaly RP.

PLoS Pathog. 2017 Dec 21;13(12):e1006740. doi: 10.1371/journal.ppat.1006740. eCollection 2017 Dec.

32.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop.

Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K.

Antiviral Res. 2018 Feb;150:93-100. doi: 10.1016/j.antiviral.2017.12.006. Epub 2017 Dec 14.

33.

Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.

Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, Gavegnano C, Schinazi RF, Poznansky MC.

Oncotarget. 2017 Oct 4;8(55):94040-94053. doi: 10.18632/oncotarget.21541. eCollection 2017 Nov 7. Erratum in: Oncotarget. 2018 Jul 13;9(54):30472. Gavegano, Christina [corrected to Gavegnano, Christina].

34.

Acute acalculous cholecystitis during zika virus infection in an immunocompromised patient.

Ono SK, Bassit L, Van Vaisberg V, Avancini Ferreira Alves V, Caldini EG, Herman BD, Shabman R, Fedorova NB, Paranaguá-Vezozzo D, Sampaio CT, Lages RB, Terrabuio D, Andraus W, Schinazi RF, Carrilho FJ.

Hepatology. 2018 May;67(5):2051-2054. doi: 10.1002/hep.29682. Epub 2018 Feb 27. No abstract available.

35.

Synthesis of (2S)-2-Chloro-2-fluororibolactone via Stereoselective Electrophilic Fluorination.

De Schutter C, Sari O, Coats SJ, Amblard F, Schinazi RF.

J Org Chem. 2017 Dec 15;82(24):13171-13178. doi: 10.1021/acs.joc.7b02245. Epub 2017 Dec 4.

PMID:
29140703
36.

Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.

Chen Z, Cox BD, Garnier-Amblard EC, McBrayer TR, Coats SJ, Schinazi RF, Amblard F.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5296-5299. doi: 10.1016/j.bmcl.2017.10.024. Epub 2017 Oct 12.

37.

Metabolism of Nucleosides and Nucleotides Prodrugs.

De Schutter C, Ehteshami M, Hammond ET, Amblard F, Schinazi RF.

Curr Pharm Des. 2017 Oct 11. doi: 10.2174/1381612823666171011104158. [Epub ahead of print]

PMID:
29022511
38.

Jak Inhibitors Modulate Production of Replication-Competent Zika Virus in Human Hofbauer, Trophoblasts, and Neuroblastoma cells.

Gavegnano C, Bassit LC, Cox BD, Hsiao HM, Johnson EL, Suthar M, Chakraborty R, Schinazi RF.

Pathog Immun. 2017;2(2):199-218. doi: 10.20411/pai.v2i2.190. Epub 2017 May 24.

39.

Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.

Sari O, Boucle S, Cox BD, Ozturk T, Russell OO, Bassit L, Amblard F, Schinazi RF.

Eur J Med Chem. 2017 Sep 29;138:407-421. doi: 10.1016/j.ejmech.2017.06.062. Epub 2017 Jun 29.

40.

A CRISPR/Cas9 approach reveals that the polymerase activity of DNA polymerase β is dispensable for HIV-1 infection in dividing and nondividing cells.

Goetze RW, Kim DH, Schinazi RF, Kim B.

J Biol Chem. 2017 Aug 25;292(34):14016-14025. doi: 10.1074/jbc.M117.793661. Epub 2017 Jul 6.

41.

Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network.

Aliota MT, Bassit L, Bradrick SS, Cox B, Garcia-Blanco MA, Gavegnano C, Friedrich TC, Golos TG, Griffin DE, Haddow AD, Kallas EG, Kitron U, Lecuit M, Magnani DM, Marrs C, Mercer N, McSweegan E, Ng LFP, O'Connor DH, Osorio JE, Ribeiro GS, Ricciardi M, Rossi SL, Saade G, Schinazi RF, Schott-Lerner GO, Shan C, Shi PY, Watkins DI, Vasilakis N, Weaver SC.

Antiviral Res. 2017 Aug;144:223-246. doi: 10.1016/j.antiviral.2017.06.001. Epub 2017 Jun 6. Review.

42.

2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.

Zhou S, Mahmoud S, Liu P, Zhou L, Ehteshami M, Bassit L, Tao S, Domaoal RA, Sari O, Schutter C, Amiralaei S, Khalil A, Ollinger Russell O, McBrayer T, Whitaker T, Abou-Taleb N, Amblard F, Coats SJ, Schinazi RF.

J Med Chem. 2017 Jul 13;60(13):5424-5437. doi: 10.1021/acs.jmedchem.7b00067. Epub 2017 Jun 26.

PMID:
28595015
43.

Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase.

Ehteshami M, Zhou L, Amiralaei S, Shelton JR, Cho JH, Zhang H, Li H, Lu X, Ozturk T, Stanton R, Amblard F, McBrayer TR, Coats SJ, Schinazi RF.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00492-17. doi: 10.1128/AAC.00492-17. Print 2017 Aug.

44.

Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.

Rimawi BH, Johnson E, Rajakumar A, Tao S, Jiang Y, Gillespie S, Schinazi RF, Mirochnick M, Badell ML, Chakraborty R.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02213-16. doi: 10.1128/AAC.02213-16. Print 2017 Jun.

45.

Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease.

Kuiper BD, Slater K, Spellmon N, Holcomb J, Medapureddy P, Muzzarelli KM, Yang Z, Ovadia R, Amblard F, Kovari IA, Schinazi RF, Kovari LC.

Biochem Biophys Res Commun. 2017 Oct 28;492(4):668-673. doi: 10.1016/j.bbrc.2017.03.108. Epub 2017 Mar 22.

PMID:
28342876
46.

Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs.

Sari O, Bassit L, Gavegnano C, McBrayer TR, McCormick L, Cox B, Coats SJ, Amblard F, Schinazi RF.

Tetrahedron Lett. 2017 Feb 15;58(7):642-644. doi: 10.1016/j.tetlet.2017.01.006. Epub 2017 Jan 4.

47.

Characterization of β-d-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus.

Ehteshami M, Tao S, Zandi K, Hsiao HM, Jiang Y, Hammond E, Amblard F, Russell OO, Merits A, Schinazi RF.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02395-16. doi: 10.1128/AAC.02395-16. Print 2017 Apr.

48.

Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.

Boucle S, Lu X, Bassit L, Ozturk T, Russell OO, Amblard F, Coats SJ, Schinazi RF.

Bioorg Med Chem Lett. 2017 Feb 15;27(4):904-910. doi: 10.1016/j.bmcl.2017.01.010. Epub 2017 Jan 6.

49.

From HCV To HBV Cure.

Schinazi RF, Asselah T.

Liver Int. 2017 Jan;37 Suppl 1:73-80. doi: 10.1111/liv.13324. Review.

50.

Substrates and Inhibitors of SAMHD1.

Hollenbaugh JA, Shelton J, Tao S, Amiralaei S, Liu P, Lu X, Goetze RW, Zhou L, Nettles JH, Schinazi RF, Kim B.

PLoS One. 2017 Jan 3;12(1):e0169052. doi: 10.1371/journal.pone.0169052. eCollection 2017.

Supplemental Content

Loading ...
Support Center